Nephros (NEPH) Stock Analysis & AI Equity Report
Nephros (NEPH) overview
Nephros (NEPH) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 18.8m and operating profit of USD 1.1m; the year-end share price was 4.88 USD and market capitalisation was USD 51.9m. Nephros is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Nephros's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Nephros
Nephros develops and markets point-of-use water filtration products for medical and commercial applications. Its medical portfolio includes microfilters and ultrafilters for infection control and dialysis water treatment, while its commercial filters address taste, odor, scale, particulates, lead, cysts and PFAS. Customers and users include healthcare facilities, dialysis settings, foodservice and hospitality businesses, laboratories, manufacturers and government facilities.
Generate the Nephros report
Nephros is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Nephros and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Nephros
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.